Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.

Autor: Chan JY; Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, 168583, Singapore. jason.chan.y.s@singhealth.com.sg.; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore. jason.chan.y.s@singhealth.com.sg., Somasundaram N; Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, 168583, Singapore.; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore., Grigoropoulos N; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore.; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Lim F; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore.; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Poon ML; Department of Haematology, National University Cancer Institute, Singapore, Singapore., Jeyasekharan A; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Yeoh KW; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore.; Division of Radiation Oncology, National University Cancer Institute, Singapore, Singapore., Tan D; Mount Elizabeth Novena Hospital, Singapore, Singapore., Lenz G; Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Ong CK; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore. cmrock@nccs.com.sg.; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore. cmrock@nccs.com.sg., Lim ST; Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, 168583, Singapore. lim.soon.thye@singhealth.com.sg.; Cancer and Stem Cell Biology, Duke-NUS Medical School, National Cancer Centre Singapore, 8 College Road, Singapore, 169857, Singapore. lim.soon.thye@singhealth.com.sg.
Jazyk: angličtina
Zdroj: Discover. Oncology [Discov Oncol] 2023 Jul 19; Vol. 14 (1), pp. 132. Date of Electronic Publication: 2023 Jul 19.
DOI: 10.1007/s12672-023-00754-8
Abstrakt: Diffuse large B-cell lymphoma (DLBCL) represents the commonest subtype of non-Hodgkin lymphoma and encompasses a group of diverse disease entities, each harboring unique molecular and clinico-pathological features. The understanding of the molecular landscape of DLBCL has improved significantly over the past decade, highlighting unique genomic subtypes with implications on targeted therapy. At the same time, several new treatment modalities have been recently approved both in the frontline and relapsed settings, ending a dearth of negative clinical trials that plagued the past decade. Despite that, in the real-world setting, issues like drug accessibility, reimbursement policies, physician and patient preference, as well as questions regarding optimal sequencing of treatment options present difficulties and challenges in day-to-day oncology practice. Here, we review the recent advances in the therapeutic armamentarium of DLBCL and discuss implications on the practice landscape, with a particular emphasis on the context of the healthcare system in Singapore.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: